The contract development and manufacturing organisation (CDMO) now has Drug Enforcement Agency (DEA) clearance to develop and manufacture Schedule IV and V controlled substances at the plant.
Pharmatek has expanded its production capacity significantly of the last 12 months, beginning in May last year when it gained approval from California State authorities to manufacture cytotoxic compounds at the facility.
More recently the contractor installed Capsugel’s Xcelodose precision powder micro-dosing technology to cater fro growing demand for good manufacturing practice (GMP) quality production capacity for clinical trial supplies.